Using Silexan to treat Posttraumatic Stress Disorder

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial evaluates the effectiveness of Silexan, a lavender oil-derived treatment, for individuals diagnosed with Posttraumatic Stress Disorder (PTSD). The study aims to address the limitations of current PTSD treatments, such as psychotherapy and antidepressant medications, which often have low efficacy and significant side effects. Participants will be randomly assigned to receive either Silexan or a placebo, and their PTSD symptoms will be assessed using standardized measures. The trial seeks to determine if Silexan can provide a well-tolerated and effective alternative for those suffering from PTSD.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Aged 18 years or over.
2. Fluent in English.
3. Meet DSM-5 criteria for PTSD, irrespective of occupation (e.g. first responder, police officer, ex-military or civilian), determined using the Mini International Neuropsychiatric Interview 7.0.2.
4. Have a score on the PTSD Checklist for DSM-5 (PCL-5) equal to or over 33.

Exclusion Criteria:

1. Are currently serving in the Australian Defence Force
2. Lifetime history of a psychotic or bipolar disorder, or dissociative identity disorder.
3. Moderate or severe alcohol or other substance use disorder within 3 months of screening.
4. Active suicidal or homicidal ideation.
5. Borderline Personality Disorder (BPD).
6. Acute or unstable medical illness or other significant medical condition, that would make participation in the trial unsafe or inappropriate.
7. Pregnancy, lactation or unwillingness to use an acceptable method of contraception (required for both males and females who are of reproductive potential and sexually active with partners of the opposite sex) through the duration of participants' involvement in the study up to and including week 16. Participants will also be advised not to donate eggs or sperm during the study period.
8. Commencement of a trauma-focussed psychotherapy (including Prolonged Exposure, Cognitive Processing Therapy and Eye Movement Desensitisation and Reprocessing) within 3 months of screening.
9. Commencement or change in dose of psychoactive medications within 4 weeks of screening.
10. Participants will be asked not to initiate psychotherapy or change the dose of psychoactive medications during the course of the study except in clinically urgent circumstances; if this becomes necessary, a decision will be made on a case-by-case basis with regard to retaining the participant or terminating their participation.
11. Severe acquired brain injury.
12. Individual is not eligible for public mental health services due to their visa status in Australia or for any other reason.
13. Any other condition that in the opinion of the research team is likely to make completion of the trial requirements infeasible.
14. Inability to understand or speak English to the extent necessary to give informed consent and complete the trial (researcher or clinician-determined).

Where it's running

• University of Melbourne
  Carlton, Victoria, Australia Recruiting
• Deakin University
  Geelong, Victoria, Australia Recruiting
• Austin Health
  Heidelberg, Victoria, Australia Recruiting
• Ramsay Clinic Albert Road
  Melbourne, Victoria, Australia Recruiting

Study contacts

• Principal investigator: Michael Berk, PhD — Deakin University
• Study coordinator: Greg Roebuck, MD
• Email: greg.roebuck@unimelb.edu.au
• Phone: +61 3 9035 4749

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Anger, Social Thinking, and PTSD in French Veterans

  This study tests whether PTSD in former French military personnel is linked to higher anger through changes in social thinking abilities.

  Recruiting Direction Centrale du Service de Santé des Armées · Draguignan · NCT07851090

• TSND-201 treatment for PTSD in adults

  This study tests two doses of TSND-201 or placebo to see if it helps adults with PTSD.

  Recruiting at 9 sites Phase 3 Transcend Therapeutics · Denver, Colorado and 8 other locations · NCT07836647

• Long-term outcomes after Hyperbaric Oxygen Therapy in veterans with TBI, PCS, or PTSD

  This study tests whether benefits from HBOT persist over time for veterans with brain injury or related conditions.

  Recruiting Phase 2 Summit Hyperbarics and Wellness · Boise, Idaho · NCT07732374

• SEE FAR CBT for Adults With PTSD

  This 12-week, one-on-one SEE FAR CBT program tests a trauma-focused therapy to see if PTSD symptoms improve in adults 18 and older.

  Recruiting Community Stress Prevention Center · Kiryat Shmona · NCT07720674

• Brief SEE FAR CBT: a short, focused therapy for adults with PTSD

  A 6-session Brief SEE FAR CBT treatment is tested against usual dynamic psychotherapy for adults with PTSD to see if it reduces symptoms.

  Recruiting Community Stress Prevention Center · Sha'ar Hanegev · NCT07710573

• MDMA Therapy for PTSD in Veterans

  This phase 2 study tests a fixed 120 mg dose of MDMA, followed by a 60 mg supplemental dose, plus therapy, to see if it helps adults who are veterans with PTSD.

  Recruiting Phase 2 Sunstone Medical · Rockville, Maryland · NCT07569159

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.